Eternity in Medical Information -- Medisurf
Search | Web Directory, News, Variable useful Information, PubMed In Medine, All
Category Select :
Items 161 ~ 180 of 26004, Page 9 of 1301
161. Statement on steps toward a new, tailored review framework for artificial intelligence-based medical devices
04/02/2019 U.S. FOOD & DRUG ADMINISTRATION
162. Bariatric Embolization Shows Promise in Treatment of Obesity
Bariatric embolization, a new, minimally invasive treatment for obesity produces weight loss and reduces appetite for up to one year, according to a new study published in the journal Radiology.
04/02/2019 Radiological Society of North America
163. Older Women Benefit Significantly When Screened with 3-D Mammography
Mammography remains an effective method for breast cancer screening in women ages 65 and older, with the addition of a 3-D technique called tomosynthesis improving screening performances even more, according to a study published in the journal Radiology.
04/02/2019 Radiological Society of North America
164. Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency’s continued efforts to bring competition to the insulin market to lower prices and expand access
04/02/2019 U.S. FOOD & DRUG ADMINISTRATION
165. FDA takes new enforcement actions as part of the agency’s ongoing effort to combat the illegal online sales of opioids
04/02/2019 U.S. FOOD & DRUG ADMINISTRATION
166. Statement on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products
04/02/2019 U.S. FOOD & DRUG ADMINISTRATION
167. Merck Completes Tender Offer to Acquire Immune Design
04/02/2019 MERCK
168. USDA, EPA, and FDA Recognize April as Winning on Reducing Food Waste Month
04/02/2019 U.S. FOOD & DRUG ADMINISTRATION
169. Merck to Hold First-Quarter 2019 Sales and Earnings Conference Call on April 30
04/02/2019 MERCK
170. Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1
Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas / Selumetinib Is a MEK 1/2 Inhibitor Being Co-Developed by AstraZeneca and Merck
04/01/2019 MERCK
171. Merck Completes Acquisition of Antelliq Corporation to Become Leader in Emerging Digital Technology for Livestock and Companion Animals
04/01/2019 MERCK
172. Statement on new efforts to advance treatment strategies for helping youth addicted to nicotine as a result of the epidemic rise in teen use of e-cigarettes
04/01/2019 U.S. FOOD & DRUG ADMINISTRATION
173. FDA warns homeopathic firms for putting patients at risk with significant violations of manufacturing quality standards
04/01/2019 U.S. FOOD & DRUG ADMINISTRATION
174. Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
KEYTRUDA is First Anti-PD-1 Therapy to be Approved in Multiple Tumor Types in China
04/01/2019 MERCK
175. Data for Merck’s KEYTRUDA® (pembrolizumab) Across Different Types of Advanced Lung Cancer Presented at AACR Annual Meeting 2019
First Presentation of Overall Survival Data from Post-Hoc Analysis of KEYNOTE-189 in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Who Have Liver or Brain Metastases / Pooled Data in Patients with Previously Treated Advanced Small Cell Lung Cancer in AACR 2019 Plenary Session and Press Conference
04/01/2019 MERCK
176. FDA approves new oral treatment for multiple sclerosis
03/29/2019 U.S. FOOD & DRUG ADMINISTRATION
177. Statement by FDA Commissioner Scott Gottlieb, M.D., Director of FDA’s Center for Drug Evaluation and Research Janet Woodcock, M.D. and Director of FDA’s Center for Biologics Evaluation and Research Peter Marks, M.D. on Expanded Access ?Looking Forward
03/29/2019 U.S. FOOD & DRUG ADMINISTRATION
178. FDA approves treatment for patients with a type of inflammatory arthritis
03/28/2019 U.S. FOOD & DRUG ADMINISTRATION
179. Statement on actions to advance our comprehensive plan to reduce tobacco-related disease and death, through new efforts to improve the tobacco product application review process, including a newly proposed rule
03/28/2019 U.S. FOOD & DRUG ADMINISTRATION
180. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for testimony before a U.S. Senate Subcommittee on Appropriations on FDA’s Fiscal Year 2020 budget
03/28/2019 U.S. FOOD & DRUG ADMINISTRATION
   
1 2 3 4 5 6 7 8 9 10
 
경기도 성남시 분당구 구미동 25-1 엘레강스 프라자 ㈜ 메디서프 | Tel : 031-896-0930 | 사업자 등록번호 : 212-81-47247
통신판매신호번호 : 경기 성남 2007-712 | 대표이사 한상욱